LATELET AGGREGATION plays an important role in normal hemostasis and is mediated by binding of fibrinogen to the membrane glycoprotein (GP) IIb-IIIa complex (integrin (YI&).'-~ Fibrinogen interacts with the GPIIbIIIa complex through the Arg-Gly-Asp (RGD) amino acid recognition ~e q u e n c e .~.~ In the resting state, platelets do not bind fibrinogen, and when platelets are activated, there is a conformational change in the GPIIb-IIIa complex leading to exposure of fibrinogen binding sites.*"' Expression of GPIIbIIIa fibrinogen binding sites after platelet activation with physiologic agonists, such as adenosine diphosphate (ADP) and thrombin, is dependent on intracellular signal transduction events"-15 and is blocked by elevation of cyclic adenosine monophosphate (cAMP).I4 Fibrinogen binding results in the expression of new antibody binding sites on the GPIIbIIIa complex referred to as "ligand-induced binding sites" PAF, adenosine diphosphate (ADP), thrombin receptor agonist peptide (SFLLRN), A23187, and 1.2-dioctonylglycerol (DiC8). Signal transduction-dependent LlBS expression (studied using MoAb 6 2 ) induced by ADP, SFLLRN, and DiC8 and signal transduction-independent LlBS expression induced by RGDS peptide or disintegrin albolabrin were normal or only minimally decreased, indicating the presence of intact ligand binding sites. We conclude that the patient's platelets have a defect in inside-out signal transduction-dependent GPllb-llla activation due t o an upstream defect in the signal transduction mechanisms rather than in the GPIIbllla complex itself. Our findings extend the spectrum of congenital mechanisms leading t o impaired aggregation from defects in GPllb-llla per se t o aberrations in signaling mechanisms.
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(LIBS)," which have an important role in aggregation and cell adhe~ion.'~.'' LIBS expression can be induced by mechanisms dependent on signal transduction pathways, as occur when platelets are activated by agonists like ADP and thrombin, and by signal transduction-independent mechanisms, which occur after exposure to small RGD-containing peptide~.'~"' Interaction of platelets with an agonist initiates the production or release of intracellular messenger molecules including Ca2+ ions and products of phosphoinositide (PI) hydrolysis (diacylglycerol and inositol 1,4,5-triphosphate). These modulate the platelet responses of shape change, aggregation, and secretion. Diacylglycerol activates protein kinase C (PKC), resulting in the phosphorylation of pleckstrin, a 47-kD platelet membrane protein. Activation of GPIIb-IIIa complexes and fibrinogen binding have been linked to PKC activation.""' Studies reported by Shattil and Brass" demonstrate that exposure of saponin-permeabilized platelets to InsP3, synthetic diacylglycerol l-oleayl-2-acetylglycerol (OAG), and the phorbol myristate acetate (PMA), results in activation of GPIIb-IIIa. Interestingly, inhibition of thromboxane A2 (TxA,) production blocked InsP,-stimulated fibrinogen receptor exposure but not the effect of PKC activators. In platelets permeabilized with complement proteins, PKC inhibitors have been shown to inhibit GPIIb-IIIa activation.'' Using the PKC inhibitor staurosporine and activators PMA and 1,2-dioctonyl glycerol (DiCx), van Willigen and Akkerman14." showed a relationship between PKC activation/pleckstrin phosphorylation and exposure of fibrinogen binding sites. More recently, Trybulec et a]' ' have demonstrated a role of PKC in exposure of fibrinogen receptors by zinc. Moreover, phosphatidic acid and lysophosphatidic acid (two lipids formed during platelet activation) modulate GPIIb-IIIa.*' There is strong evidence that cytoplasmic domains of both GPIIb (sequence GFFKR)'? and GPIIIaZ3 participate in inside-out signal transduction with changes in the spatial relationship of the subunit cytoplasmic tails leading to conformational changes in extracellular domains. Overall, these studies point to an inside-out signaling sequence of events that modulates GPIIb-IIIa activation through agonist receptors on the platelet surface. In addition, there is evidence for stimulation of outside-in intracellular signaling by ligand-occupied GPIIb-IIIa.24~25 Although the above-cited studies indicate an important role of inside-out signaling in fibrinogen receptor activation, the role of PKC activation in this response is not fully clarified. GPIIIa is phosphorylated on activation, but there is little evidence that it leads to fibrinogen receptor exposure.26 During the course of our studies in patients with congenital defects in platelet function, we identified a patient with markedly impaired, agonist-stimulated phosphorylation of pleckstrin, the protein phosphorylated by PKC. We have used platelets from this patient to examine the relationship between activation of PKC and that of GPIIb-IIIa. Our goals were to determine whether this patient with a defect in signal transduction mechanisms would manifest impaired activation of GPIIb-IIIa and to characterize the mechanisms leading to the markedly abnormal primary wave of aggregation noted in this patient. FITC-fibrinogen was separated from free FITC using Sephadex G25 column PD-10 (Pharmacia LKB Biotechnology, Piscataway, NJ) and stored at 4°C until used. The cY-chymotrypsin type I-S (from bovine pancreas), soybean trypsin-chymotrypsin inhibitor, and all other chemicals used in this study were purchased from Sigma Chemical Co, St Louis, MO. Aggregation and secretion. Blood was collected in l/10 volume of 3.8% sodium citrate and centrifuged at 18Og for 15 minutes at room temperature to obtain platelet-rich plasma (PRP). Platelet aggregation responses were monitored using a Chrono-Log (Havertown, PA) dual channel aggregometer as described previously." The extent of aggregation was expressed as a percentage taking the light transmission through PRP and platelet-poor plasma to be 0% and lOO%, respectively.
MATERIALS AND METHODS

Par&t
For assessing 'JC-serotonin secretion, platelets were incubated for 30 minutes at room temperature with 0.25 prnoll L of 5hydroxy(side chain-2-"'C) tryptamine creatine sulfate (50 mCi/mol/L).
Secretion was expressed as a percent of total "C-serotonin incorporated that is released after platelet stimulation. For personal use only. on August 30, 2017 . by guest www.bloodjournal.org From tion of PRP for S minutes with the agonist, using a radioimmunoassay for thromboxane Measurement of pleckstrin and myosin light chain phosphorylation. Blood was collected by venipuncture into I/7 volume of acid citrate dextrose buffer (85 mmoVL trisodium citrate, 78 mmol/L citric acid, 1 11 mmol/L dextrose) and centrifuged at 18Og for 20 minutes to obtain PRP. PRP was centrifuged at 1,000g for 1 S minutes in the presence of hirudin (0.05 U/mL) and apyrase (IO pg/mL) and the platelet pellet was resuspended in 1/3 volume of autologous plasma. Platelet suspension was incubated at 37°C for 60 minutes with 32P-orthophosphate (0.4 mCilmL). The platelets were then filtered through a Sepharose 2B column equilibrated with Caz+ freeTyrode's buffer, pH 7.4, containing 136 mmol/L NaCl, 2.7 mmol/ L KCI, 0.47 mmolL NaH2P0,, 12 mmoVL NaHC03, 2 mmol/L MgCI2, 5.5 mmol/L dextrose, and 0.2% bovine serum albumin (BSA). The platelet counts were adjusted to 3 X 10*/mL to 4 X IOx/ mL. Platelet suspensions labeled with 32P-P04 (0.4 mCi/mL) were activated with 400 nmoVL PAF, 0.05 U/mL thrombin, 200 pmol/L DiCx, or 1 pmol/L A23187. The reactions were terminated at various intervals (0 to 300 seconds) by transferring 0.5 mL aliquots of the sample to tubes containing an equal volume of 0.6 N HC104. The sample was centrifuged in an Eppendorf Centrifuge S415 (Brinkmann Instrumental Inc, Westbury, NY) at 14,OOOg for S minutes. The pellet was washed once with distilled water and subjected to 13.5% sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE). The gels were dried and subjected to autoradiography using DuPont Cronex video imaging film (E.I. DuPont CO, Wilmington, DE). The bands on the gel corresponding to the 47-kD band (pleckstrin) were cut, placed in liquid scintillation cocktail (Betafluor; National Diagnostic, Atlanta, CA), and counted for radioactivity. The results were expressed as fold of the basal radioactivity in pleckstrin. Although other platelet phosphoproteins of similar size may comigrate, the change in phosphorylation of the 47-kD band after platelet activation has generally been considered to reflect pleckstrin phosphorylation.
Measurement of cytoplasmic Ca2+ concentration. Intracellular ionized calcium concentrations ([Ca2']i) were measured using fura-2 as the indicator, as described previo~sly.'~ Fluorescence was recorded (excitation, 340 nm; emission, S 10 nm) using a spectrofluorimeter (model LS-S, Perkin Elmer, Oakbrook, IL). The [Ca*']i concentrations were calculated as described previously." Flow cytometty analysis. Blood was collected in 1/10 volume of 3.8% sodium citrate from the patient and normal donors who had taken no medication for at least 10 days. PRP was collected by centrifuging the citrated blood at 18Og for 15 minutes at room temperature. PRP was added to 12 X 75-mm polypropylene tubes, and an appropriate volume of Tyrode's buffer, pH 7.4 (S mmol/L Hepes, 2 mmoVL MgC12, 0.3 mmo1L NaH2P04, 3 mmol/L KCI, 134 mmol/ L NaC1, 12 mmoVL NaHC03, 0.35% BSA, and 0.1% glucose), was added to make the platelet final concentration I X 10*/mL. Platelets (50 pL) were incubated with FITC-conjugated MoAbs PACl (SO pg/mL), 10ES (50 pg/mL), AzA9 (SO pg/mL), or Ab62 (SO pg/mL) in the presence of a specific agonist at room temperature for 15 minutes without stirring. Samples were then diluted to 0.5 mL with Tyrode's buffer and analyzed on an Epics Elite flow cytometer (Coulter CO, Miami, FL). Platelets (10,OOO in each sample) were analyzed at 100 mW laser beam (coherent Innovor 300) for FITC fluorescence to quantitate the amount of platelet-bound antibody. Results were expressed as mean platelet fluorescence units or as histograms of log platelet fluorescence intensity in arbitrary units on the abscissa and platelet number on the ordinate. In some experiments, the PRP was subjected to gel filtration using sepharose CL 2B column, and platelets were eluted with Tyrode's buffer (pH 7.4) without added BSA. These platelet suspensions (1 X IO'/mL) were used to examine the binding of nonspecific mouse IgG and 10ES using FITC-labeled anti-mouse IgG as the second antibody. In these experiments, platelet suspensions (SO pL) were incubated with the murine IgG or 10E5 (SO pg/mL) for IS minutes at room temperature and then with FITC-labeled anti-mouse IgG for IS minutes. The samples were diluted with Tyrode's buffer and analyzed by flow cytometry as described above.
Treatment of platelets with m-chymotrypsin results in the exposure of fibrinogen binding site^,',^',^* which is signal transduction-independent and unaffected by PGIz and stauro~porine.'~~~'.~~ We examined the binding of FITC-labeled fibrinogen and PAC1 in platelets treated with a-chymotrypsin and in the presence of Iloprost. Gelfiltered platelets (2 X lO*/mL) in Tyrode's buffer without BSA were incubated at 37°C for S minutes with a-chymotrypsin (SO0 pg/mL) in the presence of 28 nmol/L Iloprost. The a-chymotrypsin was neutralized with a soybean trypsinkhymotrypsin inhibitor ( I mg/ mL), and platelets were pelletted by centrifugation. The platelet pellets were resuspended in Tyrode's buffer containing Iloprost (28 nmoVL). Chymotrypsin-treated platelet suspension (1 X IOx/mL; 50 pL) was incubated with FITC-labeled fibrinogen (200 pg/mL) or PACl (SO pg/mL) for IS minutes at room temperature without stirring and was examined for binding of fibrinogen or PACl using flow cytometry as described earlier. Control platelets were incubated with Tyrode's buffer instead of a-chymotrypsin.
RESULTS
Platelet aggregation and secretion.
Platelet aggregation and secretion were studied in the patient on multiple occasions over several years with consistently abnormal results. Platelet aggregation and secretion in PRP in response to ADP (8 pmoVL), PAF (20 pmoVL), and U46619 (2 pmoV L) were impaired (Fig l) , as were responses to epinephrine (8 pmolL), arachidonic acid (1 mmoVL), and collagen (1.25 pg/mL; not shown). The most striking abnormalities were observed in response to PAF (200 nmol/L and 20 pmoVL) and U46619 (2 pmolL; Fig 1) ; the primary wave or initial aggregation was also markedly blunted. Diminished responses were also observed in response to cell-permeable activators, divalent ionophore A23187 (10 pmoVL), and PKC activator DiCs (200 pmolL; Fig 1) . The slopes of initial aggregation were blunted in the patient compared with those of normal subjects. The mean values (two to three studies) of the slopes in the patient and the range of values in five normal subjects are as follows: ADP (8 pmoVL): patient, 34 arbitrary units (U); normals, 45 to 73 U; PAF (20 pmoVL): patient, 25 U; normals, 58 to 100 U; A23187 (10 pmoVL): patient, 27 U; normals, 55 to 100 U; and DiC, (200 pmoVL): patient, 7 U; normals, 17 to 25 U. Exposure of platelets to a combination of DiC, with PAF or ADP enhanced the aggregation and secretion responses but not to the level noted in normal PRP. However, both responses to a combination of 200 pmol/L of DiCs and 10 pmol/L A23187 were entirely normal.
Platelet dense granule content and thromboxane A2 production. Content of ATP and ADP and the ATP:ADP ratio in patient's platelets were normal, thereby excluding dense granule storage pool deficiency. Thromboxane A2 production in PRP was normal in response to 1 U/mL thrombin (35 pmol/108 platelets; normal range, 21 to 146 pmol/108 platelets; n = 1 1) and 1 mmoVL arachidonic acid (patient, 167 pmol/lO* platelets; normal range, 128 to 709 prnol/1O8 platelets; n = 8).
For Phosphorylation of pleckstrin and myosin light chain and calcium mobilization.
In the patient, platelet pleckstrin phosphorylation was markedly diminished after activation with PAF (4 and 400 nmoVL) and thrombin (0.05 U/mL) (Fig 2) . At higher thrombin concentrations (5 U/mL), it was also lower than in normal controls; at 30 seconds, it was 2.15-fold of basal in the patient compared with 3.62-to 6.59-fold in 14 normal subjects. At 1 minute, pleckstrin phosphorylation was 3.03-and 2.77-fold of basal in two studies in the patient compared with 3.64-to 7.32-fold in 15 normal subjects. Pleckstrin phosphorylation was diminished in response to 1 pmoVL A23187 (patient, 1.72-and 1.21-fold of basal v 2.26-to 3.61-fold in six normal controls). After activation with 200 pmoVL Dic,,, pleckstrin phosphorylation was normal in the patient. In response to ADP, we observed very minimal or inconsistent pleckstrin phosphorylation even in normal platelets. Myosin light chain phosphorylation was impaired in response to PAF (400 nmoVL) and thrombin (0.05 U/mL). With thrombin (0.5 U/&), myosin phosphorylation at l minute showed a 1.8-fold increase over basal in the patient compared with 2.36-to 3.94-fold over basal in nine normal subjects. In response to 200 pmoVL DiCs and 1 p m o m A23 187, myosin phosphorylation at 1 minute also was blunted in the patient. Studies on Caz+ mobilization using fura-2-loaded platelets showed that basal and peak [Ca"] were normal in the patient after platelet activation with thrombin (0.05 and 0.5 U/mL) and ADP (25 pmoVL) in the presence of 1 mmoVL external Ca2+. Binding of MoAbs lOE.5, A&, and PACl by flow cytometry. Binding of MoAbs 10E5 and A2A9 (which bind to both activated and resting forms of GPIIb-IIIa) by patient platelets was comparable with that in normal platelets (Fig 3) , suggesting that normal levels of GPIIb-IIIa were present on patient platelets. In control experiments, we examined the Fluorescence intensity Iloprost had only a slight inhibitory effect (Fig S) , indicating that LIBS expression induced by these peptides is signal transduction-independent. In patient platelets, MoAb 62 binding by albolabrin and RGDS peptide were only slightly decreased compared with that in normal platelets (Fig 5) . indicating that the patient platelets have an essentially intact ligand-binding ability, as well as the capacity to express LIBS by signal transduction-independent mechanisms.
Signal trnrtsdltctiorl-dependent LIBS expression. Signal transduction-dependent LlBS expression through cell activation was induced by ADP (S pmol/L). TRAP (25 pmol/L), PAF (200 nmol/L and 20 ymol/L), DiCR (1 00 pmol/L) and A23 187 (S pmol/L) (Fig 6) . In normal platelets, Iloprost completely blocked LIBS expression induced by these agonists (Fig 6) . indicating its dependence on signal transduction mechanisms. In patient platelets, MoAb 62 binding induced by ADP, TRAP, and DiCx in the absence of lloprost was comparable with that in normal platelets. It was minimally decreased with A23 187. In contrast, a striking decrease was noted with PAF 200 nmol/L and 20 pmol/L (Fig 6) . Thus, the most striking abnormality in LIBS expression occurred in response to the agonist (PAF) with the most impaired PAC1 expression.
Binding of jihrinogen and PAC1 to a-chymottyyintreated platelets. To obtain additional information on the ligand-binding ability of patient platelets, we studied the binding of FITC-labeled fibrinogen and PAC1 in platelets treated with a-chymotrypsin, which is known to induce fibrinogen binding that is not affected by elevation in CAMP by agents such as prostaglandin E,.".37.'X The binding of FITC-labeled fibrinogen in patient platelets was comparable 
B
with that in normal platelets in the presence of Iloprost (Fig  7) . The binding of PAC1 was also comparable in similarly treated patient and normal platelets (Fig 7) .
DISCUSSION
The major finding in this report is that the patient's platelets have a defect in receptor-mediated signal transductiondependent activation of GPIIb-IIIa that manifests as impaired aggregation in response to multiple agonists and impaired secretion in response to weak agonists (ADP, PAF, and epinephrine). Elegant studies exploiting several specific antibodies have permitted delineation of a series of discrete events that are related to platelet aggregation." These include (1) agonist-induced activation of the GPIIb-IIIa complex leading to the exposure of ligand (fibrinogen)-binding site, (2) ligand binding, and (3) post-occupancy events that follow ligand binding, including expression of the LIBS. In our patient, GPIIb-IIIa complexes are present in normal amounts on the platelet surface, as evidenced by normal binding of MoAbs IOE5 (Fig 3) and A2A9 and of FITC-labeled fibrinogen to chymotrypsin-treated platelets (Fig 7) . However, GPIIb-IIIa activation is impaired, as revealed by diminished For PAC1 binding after exposure to several different agonists (Fig 4) . Impaired aggregation may occur due to a deficiency of GPIIb-Illa complexes. as in classical thrombasthenia,"' or due to abnormalities in ligand-binding capacity of GPIlbIIIa, as reported in thrombasthenia variants such as the Cam variant.'"''' In our patient, LlBS expression (MoAb 62 binding) was normal after exposure to small peptides, RGDS, and albolabrin (Fig 5) . which bind GPlIb-llla even in unactivated platelets to induce expression of LIBS'h'").J': this indicates that ligand binding is intact. This conclusion is supported by normal fibrinogen binding induced by a-chymotrypsin, which induces ligand binding by proteolytic cleavage of GPIIb-IIIa,'7~'X a process that is signal transduction-indepenThus, the defect in our patient is in GPIIb-IIIa activation and attendant conformational change, rather than in ligand binding. Moreover, although GPIIb-llla activation was impaired in our patient in response to several agonists, it was normal under certain activation conditions, such as high-dose ADP (60 pmol/L) or combined stimulation with A23 1 X7 and DiC,. These findings provide evidence that the GPIIb-llla complex per se is essentially intact, and its impaired activation results from abnormalities in upstream signaling events that regulate its activation. This would also make it unlikely that our patient has one of the variants of Glanzmann thrombasthenia, which are characterized by abnormalities in the GPIlb-I1Ia molecular complex along with quantitative defects in many patients.'.''"'.'' A similar abnormality in GPIlb-IIla activation has been described in a patient with myelofibrosis. an acquired platelet disorder.'" dent. I5.37.7x
Given the lifelong history in our patient, we suggest that the abnormality is congenital, supported also by a lifelong history of easy bruising and thrombocytopenia in the patient's father (deceased).
The findings in our patient extend the spectrum of potential congenital platelet mechanisms leading to impaired aggregation from abnormalities in GPIlb-IIIa per se to aberrations in upstream events of platelet signal transduction that govern its activation. Thus, defects in primary aggregation may be viewed as related to defects in ( I ) the GPlIb-IIla complex per se (which includes Glanzmann thrombasthenia and variants) and (2) GPllb-IIIa function, resulting from abnormalities in the intracellular signaling events that regulate its activation. Our patient exemplifies the second mechanism and, to our knowledge, such a congenital defect has hitherto not been described. It is tempting to speculate that defects in aggregation (primary). often observed in patients with bleeding manifestations. may be more likely due to abnormalities in intracellular signaling events than in GPIIbIIIa molecule. Thus, it is conceivable that some of the patients described by Lages and Weiss" with impaired initial aggregation responses to weak agonists, such as ADP, epinephrine, and U46619, also have abnormal integrin activation related to defective signal transduction events. In one of these patients, abnormalities in phosphoinositide hydrolysis" and pleckstrin phosphorylation were subsequently described.J5 Kornecki et al"' have described a patient with markedly abnormal platelet aggregation, normal levels of radiolabeled platelet surface glycoproteins, and markedly impaired '251-fibrinogen binding sites. However, pleckstrin phosphorylation was normal?h Our studies in normal platelets extend previous reports""' that LIBS expression may be induced by signal transductiondependent and -independent mechanisms. LlBS expression after exposure to smaller peptides (RGDS and albolabrin) occurred largely independent of intracellular events, in contrast with that mediated by surface receptor agonists such as ADP, PAF, and thrombin, which was strongly dependent on signal transduction. In our patient, ADP-and thrombininduced LIBS expression was normal (Fig 6) , even though PAC1 binding was abnormal (Fig 4) . RGDSI9 and albolabin4' increase binding of MoAb 62 to platelets by changing conformation of CY,& and expressing the LIBS epitope.
Although anti-LIBS epitope and the ligand-binding site are distinct structures, there is a cooperativeness between these sites: ligand binding promotes LlBS expression and binding of anti-LIBS antibody enhances ligand binding." Moreover, fibrinogen binding to its receptor enhances cellular signaling leading to the increased fibrinogen-binding affinity to GPIlbIlla.'5 For these reasons, it is difficult to completely separate signal transduction-dependent and signal transduction-independent LIBS expression, and LIBS expression may not be totally independent. It is conceivable that slightly decreased binding of a MoAb 62 antibody to patient platelets stimulated by RGDS and albolabrin (Fig 5) may also reflect the defect in intracellular activation mechanisms.
A number of studies have linked PKC activation to GPIIbIlla activation."."." In our patient, we provide evidence of a defect in pleckstrin phosphorylation in response to throm- (Fig 2) . Our findings strongly support previous findings in normal platelets12"6 that activation of GPIIb-IIIa is, indeed, regulated by intracellular events. We propose that the observed defective integrin activation in our patient is related to the upstream abnormality in intracellular events including pleckstrin phosphorylation. These findings may provide additional support for a role of PKC in GPIIb-IIIa activation, at least in response to some agonists. The precise mechanisms by which PKC regulates GPIIb-IIIa activation await clarification. Interestingly, in our patient, DiCB-induced pleckstrin phosphorylation was normal, implying that the yet-undefined defect lies further upstream and not directly in either PKC or in its substrate, pleckstrin.
ADP and PAF are both weak platelet agonists,'" and ADP is a particularly weak inducer of phospholipase C activation: ' with some studies not detecting hydrolysis of 32P-labeled phosphoin~sitides.~~ In our studies in normal platelets, pleckstrin phosphorylation in response to ADP was very low compared with that with other agonists (not shown). Yet, our studies show GPIIb-IIIa activation with ADP was more intense than with PAF. In the patient, PACl binding, GPIIb-IIIa activation, and initial slopes of aggregation are more strikingly abnormal with PAF, and, in fact, high ADP concentrations lead to near normal PACl binding, while a similar effect is not noted with PAF. This may suggest that ADP and PAF induce GPIIb-IIIa activation by different mechanisms, and PAF may have a greater dependence on products of phospholipase C activation than ADP. There is evidence of major differences in another platelet responses (Ca2+ mobilization) induced by these agonists." Sage and Rinkso have demonstrated that an increase in [Ca2']i after activation with PAF, thrombin, and U46619 occurs after a delay of 200 to 400 milliseconds, while with ADP, it is markedly shorter, occurring without measurable delay. These studies have suggested that ADP evokes Ca2+ influx using a different transduction system, more closely coupled to Ca2+ entry system, than by other agonists, where the delay is sufficient for one or more biochemical steps to occur between activation and Caz+ flux. Activation of GPIIb-IIIa by different agonists may be differentially regulated by intracellular activation events. ADP may be relatively more effective in inducing GPIIb-IIIa expression also by direct effects on membrane. The apparent lack of correlation between pleckstrin phosphorylation and GPIIb-IIIa activation observed after activation with ADP leads us to conclude that ADP-induced fibrinogen receptor exposure may be only minimally dependent on PKC activation, and more importantly, that such a relationship is clearly agonist-dependent.
Our observations are compatible with the conclusions that the impaired aggregation in our patient arises (1) due to an abnormality in GPIIb-IIIa activation despite the presence of adequate amounts of this integrin on platelet surface with intact ligand-binding ability, and ( 2 ) that it is related to a defect in the signal transduction mechanisms that couple agonist receptors to GPIIb-IIIa activation rather than in the GPIIb-IIIa complex itself. The finding that pleckstrin phosphorylation is impaired upon platelet activation lends support to the paradigm that, at least in response to some agonists (eg, PAF, thrombin), PKC activation constitutes one of the mechanisms that modulate GPIIb-IIIa activation and fibrinogen binding. However, such a relationship may not be equally operative for other agonists (eg, ADP). Our patient provides strong evidence that abnormal aggregation may result not only from defects in GPIIb-IIIa per se but also from aberrations in upstream events of platelet signal transduction.
